Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annu...(nal ultrasound laparoscopic techni...),Health

techniques, renal ablation, needle ablation of the kidney and

cryoablation of the prostate.

About Endocare

Endocare, Inc. -- http://www.endocare.com -- is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

Statements contained in this release that are not historical facts are forward-looking statements that involve risks and uncertainties. Among the important factors which could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, those discussed in "Risk Factors" in the Company's Forms 10-K, Forms 10-Q, and other filings with the Securities and Exchange Commission. Such risk factors include, but are not limited to, uncertainty regarding the effects of the studies described in this press release and any future follow up data. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. The Company undertakes no obligation to revise, or update publicly, any forward-looking statements for any reason.

Investor Contact:

Matt Clawson

Allen & Caron, Inc.

(949) 474-4300

matt@allencaron.com

Media Contact:

Len Hall

Allen & Caron, Inc.

(949) 474-4300

len@allencaron.com

For Additional Information:

Craig T. Davenport, CEO

Michael
'/>"/>